We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Single Blood Test Could Detect Different Types of Cancer at Early Stages

By LabMedica International staff writers
Posted on 14 May 2025

Currently, reliable screening for only a few types of cancer is available, such as those affecting the breast, bowel, cervix (neck of the womb), and lung for individuals at high risk. More...

While these screenings have been successful in reducing death rates from these cancers, they can sometimes lead to false positives and overdiagnosis. A groundbreaking single blood test, capable of detecting chemical signals from multiple types of cancer, may now be able to identify the disease in its early stages, making it easier to treat for nearly 50% of patients.

A study led by Queen Mary University of London (QMUL, London, UK) sought to determine if a multi-cancer early detection (MCED) test, administered annually or every two years, could detect cancer at an early stage and thereby improve patient outcomes. The study’s findings, published in BMJ Open, suggested that MCED tests have the potential to identify 31–49% of cancers at stages I-II that would otherwise be detected only at stages III-IV. The researchers used an existing disease progression model for various cancers to predict the effects of regular screening with an MCED test on cancer diagnosis times and patient survival under different screening schedules. The cancers included in the study span a wide range, including those of the anus, bladder, breast, cervix, bowel/rectum, esophagus, gallbladder, head and neck, kidney, liver/bile duct, lung, ovary, pancreas, prostate, sarcoma (soft tissues/bone), stomach, thyroid, uterus, and the blood cancers such as leukemia, lymphoma, melanoma, and myeloid neoplasms.

The modeling results indicated that all MCED screening intervals showed better early-stage detection rates compared to standard care alone. The shift to earlier stages of diagnosis was particularly significant for tumors with faster growth, which tend to remain at stage I for 2 to 4 years before progressing. In contrast, tumors with fast, aggressive growth (progressing within 1 to 2 years from stage I) showed a smaller effect from early detection. The study found that annual MCED screening yielded more diagnoses and prevented more deaths within 5 years than screening every two years. In a scenario involving 392 individuals diagnosed annually with aggressive cancers that would lead to death within 5 years, biennial MCED screening could have prevented 54 (14%) deaths, while annual MCED screening could have prevented 84 (21%) deaths.

“When choosing how often to offer different type of cancer screening there is a balance to be made between preventing more cancer deaths and obtaining the greatest benefit for the costs and inconvenience of screening. Generally, the faster the cancer develops the more frequently one needs to screen,” said Professor Peter Sasieni, Professor of Cancer Epidemiology, Centre Co-Lead for the Centre for Cancer Screening, Prevention and Early Diagnosis, at QMUL. “We modelled what might be appropriate for a screening test that can detect all types of cancer. If screening works, even screening once every three years would prevent a substantial proportion of advanced stage cancers, but more frequent screening is needed to maximise the potential benefit. Depending on pricing, it seems likely that annual testing might deemed the most appropriate for blood-based multi-cancer screening.”


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Alcohol Testing Device
Dräger Alcotest 7000
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Virtual staining of label-free tissue in imaging mass spectrometry (Photo courtesy of Ozcan Lab/UCLA)

Deep Learning Advances Imaging Mass Spectrometry with Virtual Histological Detail

Imaging mass spectrometry (IMS) is a powerful technique that can map thousands of molecular species in biological tissues with exceptional chemical specificity. However, IMS is hindered by relatively low... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.